A Single-centre, Double-blind, Double-dummy, Randomised, Placebo Controlled, Four-period Crossover Study in Healthy Male Volunteers, to Assess the Effect on QT/QTc Interval of Single Oral Doses of AZD1981 (200 mg and 2000 mg) Using Moxifloxacin (Avelox) as a Positive Control.

Trial Profile

A Single-centre, Double-blind, Double-dummy, Randomised, Placebo Controlled, Four-period Crossover Study in Healthy Male Volunteers, to Assess the Effect on QT/QTc Interval of Single Oral Doses of AZD1981 (200 mg and 2000 mg) Using Moxifloxacin (Avelox) as a Positive Control.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Jun 2011

At a glance

  • Drugs AZD 1981; Moxifloxacin
  • Indications Acute exacerbations of chronic bronchitis; Acute sinusitis; Asthma; Bacterial infections; Chronic obstructive pulmonary disease; Community-acquired pneumonia; Intra-abdominal infections; Respiratory tract infections; Skin and soft tissue infections; Tuberculosis
  • Focus Pharmacodynamics
  • Most Recent Events

    • 27 Jun 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Feb 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 27 Dec 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top